| Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
|---|
| Canagliflozin | hsa00500 | Starch and sucrose metabolism | 3.88E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | | Canagliflozin | hsa00520 | Amino sugar and nucleotide sugar metabolism | 6.13E-03 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | | Canagliflozin | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 2.03E-02 | 1 | P35557 | GCK | More | | | Canagliflozin | hsa00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 3.60E-03 | 2 | P06865, O75752 | HEXA, B3GALNT1 | More | | | Canagliflozin | hsa00730 | Thiamine metabolism | 5.44E-04 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | | | Canagliflozin | hsa00740 | Riboflavin metabolism | 4.03E-02 | 1 | P24666 | ACP1 | More | | | Canagliflozin | hsa03060 | Protein export | 7.08E-03 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | | Canagliflozin | hsa04064 | NF-kappa B signaling pathway | 2.69E-02 | 9 | P10415, O00463, P01375, Q04759, Q13077, Q16548, Q8WV28, P24522, P09341 | BCL2, TRAF5, TNF, PRKCQ, TRAF1, BCL2A1, BLNK, GADD45A, CXCL1 | More | | | Canagliflozin | hsa04071 | Sphingolipid signaling pathway | 2.06E-02 | 7 | Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q9UQC2 | EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, GAB2 | More | | | Canagliflozin | hsa04080 | Neuroactive ligand-receptor interaction | 2.54E-02 | 7 | P08311, Q15722, Q9H228, P21462, P21730, Q16581, P35318 | CTSG, LTB4R, EDG8, FPR1, C5AR1, C3AR1, ADM | More | | | Canagliflozin | hsa04114 | Oocyte meiosis | 1.92E-02 | 4 | Q9Y6D9, P51812, Q02750, Q14738 | MAD1L1, RPS6KA3, MAP2K1, PPP2R5D | More | | | Canagliflozin | hsa04217 | Necroptosis | 1.71E-02 | 4 | P23458, Q9NQC7, P15104, O75351 | JAK1, CYLD, GLUL, VPS4B | More | | | Canagliflozin | hsa04340 | Hedgehog signaling pathway | 1.43E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | | Canagliflozin | hsa04613 | Neutrophil extracellular trap formation | 1.37E-02 | 12 | O60603, P05164, P08246, Q9UM07, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | | | Canagliflozin | hsa04621 | NOD-like receptor signaling pathway | 2.64E-02 | 10 | Q16539, Q14643, P10599, Q9H1Y0, P43490, O00463, P10415, P01375, P09341, P12838 | MAPK14, ITPR1, TXN, ATG5, PBEF1, TRAF5, BCL2, TNF, CXCL1, DEFA4 | More | | | Canagliflozin | hsa04657 | IL-17 signaling pathway | 1.28E-02 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | | Canagliflozin | hsa04658 | Th1 and Th2 cell differentiation | 3.21E-03 | 9 | Q04759, P20963, P09693, Q16539, Q14765, P42226, P23771, Q9UL17, P13765 | PRKCQ, CD247, CD3G, MAPK14, STAT4, STAT6, GATA3, TBX21, HLA-DOB | More | | | Canagliflozin | hsa04659 | Th17 cell differentiation | 3.18E-02 | 8 | Q04759, Q16539, P42226, P13765, Q9UL17, P23771, P09693, P20963 | PRKCQ, MAPK14, STAT6, HLA-DOB, TBX21, GATA3, CD3G, CD247 | More | | | Canagliflozin | hsa04660 | T cell receptor signaling pathway | 1.07E-02 | 9 | P01375, Q04759, O95267, Q08881, P20963, P09693, P01732, Q16539, P49841 | TNF, PRKCQ, RASGRP1, ITK, CD247, CD3G, CD8A, MAPK14, GSK3B | More | | | Canagliflozin | hsa04724 | Glutamatergic synapse | 1.08E-02 | 3 | P51828, P62873, P15104 | ADCY7, GNB1, GLUL | More | | | Canagliflozin | hsa04727 | GABAergic synapse | 2.32E-02 | 3 | P51828, P62873, P15104 | ADCY7, GNB1, GLUL | More | | | Canagliflozin | hsa04914 | Progesterone-mediated oocyte maturation | 3.88E-02 | 3 | Q9Y6D9, P51812, Q02750 | MAD1L1, RPS6KA3, MAP2K1 | More | | | Canagliflozin | hsa04919 | Thyroid hormone signaling pathway | 2.44E-02 | 3 | Q02750, Q15788, P08237 | MAP2K1, NCOA1, PFKM | More | | | Canagliflozin | hsa04950 | Maturity onset diabetes of the young | 2.03E-02 | 1 | P35557 | GCK | More | | | Canagliflozin | hsa05145 | Toxoplasmosis | 3.96E-02 | 2 | P28068, Q16787 | HLA-DMB, LAMA3 | More | | | Canagliflozin | hsa05150 | Staphylococcus aureus infection | 4.37E-02 | 6 | P21730, P21462, O75015, P13765, Q16581, P12838 | C5AR1, FPR1, FCGR3B, HLA-DOB, C3AR1, DEFA4 | More | | | Canagliflozin | hsa05165 | Human papillomavirus infection | 2.01E-02 | 3 | Q16787, Q02930, Q13315 | LAMA3, CREB5, ATM | More | | | Canagliflozin | hsa05166 | Human T-cell leukemia virus 1 infection | 2.91E-02 | 3 | Q02930, P28068, Q13315 | CREB5, HLA-DMB, ATM | More | | | Canagliflozin | hsa05169 | Epstein-Barr virus infection | 4.32E-02 | 11 | P13765, O00463, P16070, P10415, Q16539, P24522, Q8WV28, P01375, O60603, P09693, P20963 | HLA-DOB, TRAF5, CD44, BCL2, MAPK14, GADD45A, BLNK, TNF, TLR2, CD3G, CD247 | More | | | Canagliflozin | hsa05202 | Transcriptional misregulation in cancer | 8.07E-04 | 14 | Q15532, P14780, P27930, Q16548, Q13077, Q15652, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P24522 | SS18, MMP9, IL1R2, BCL2A1, TRAF1, JMJD1C, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, GADD45A | More | | | Canagliflozin | hsa05217 | Basal cell carcinoma | 1.43E-02 | 4 | Q13635, P49841, Q9UJU2, P24522 | PTCH1, GSK3B, LEF1, GADD45A | More | | | Canagliflozin | hsa05321 | Inflammatory bowel disease | 7.62E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P42226, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, STAT6, GATA3 | More | |
|
